Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma

Overview

Journal Curr Treat Options Oncol

Specialty Oncology

Date 2021 Jun 10

PMID 34110508

Citations 13

Authors

Kazhan Mollazadegan

Staffan Welin

Joakim Crona

Affiliations

Soon will be listed here.

Abstract

Treatment recommendations for advanced gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are based on uncontrolled, mainly retrospective data. Chemotherapy can offer palliative relief, but long-lasting complete responses or cures are rare. The European Neuroendocrine Tumour Society (ENETS) and European Society for Medical Oncology (ESMO) recommend platinum-based chemotherapy as first-line treatment. This has been the golden standard since the late 1980s and has been evaluated in mostly retrospective clinical studies. However, progression is inevitable for most patients. Unfortunately, data on effective second-line treatment options are scant, and ENETS and ESMO recommendations propose fluorouracil- or temozolomide-based chemotherapy schedules. As such, there is a huge unmet need for improved care. Improved knowledge on GEP-NEC biology may provide a pathway towards more effective interventions including chemotherapy, targeted gene therapy, peptide receptor radionuclide therapy, as well as immune checkpoint inhibitors. The review summarises this current state of the art as well as the most promising developments for systemic therapy in GEP-NEC patients.

Citing Articles

Phase II Study of Nanoliposomal Irinotecan (Nal-IRI) with 5-Fluorouracil and Leucovorin in Refractory Advanced High-Grade Neuroendocrine Cancer of Gastroenteropancreatic (GEP) or Unknown Origin.

Mukherjee S, Pattnaik H, Sonti S, Ramesh M, Jain P, Ramirez R Cancers (Basel). 2025; 17(2).

PMID: 39858006 PMC: 11763628. DOI: 10.3390/cancers17020224.

Development and validation of a nomogram to predict overall survival of gastroenteropancreatic neuroendocrine carcinoma: a SEER database analysis.

Chen Q, Guo Y, Wang Z, Chen X, Tian C, Zheng J Transl Cancer Res. 2024; 13(9):4678-4693.

PMID: 39430841 PMC: 11483443. DOI: 10.21037/tcr-23-2215.

Metastatic Small Cell Carcinoma of the Stomach.

Gunay M, Leone C, Albayati O, Mohamed A, Anyadike N ACG Case Rep J. 2024; 11(10):e01540.

PMID: 39421734 PMC: 11484663. DOI: 10.14309/crj.0000000000001540.

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.

Falkman L, Sundin A, Skogseid B, Botling J, Bernardo Y, Wallin G Ups J Med Sci. 2024; 129.

PMID: 38716076 PMC: 11075439. DOI: 10.48101/ujms.v129.10660.

Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma.

McKinley B, Coston T, Starr J Oncologist. 2024; 30(1).

PMID: 38478398 PMC: 11783290. DOI: 10.1093/oncolo/oyae034.

References

Strosberg J, Nasir A, Coppola D, Wick M, Kvols L . Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol. 2009; 40(9):1262-8. DOI: 10.1016/j.humpath.2009.01.010. View

Pavel M, Oberg K, Falconi M, Krenning E, Sundin A, Perren A . Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(7):844-860. DOI: 10.1016/j.annonc.2020.03.304. View

Idrees K, Padmanabhan C, Liu E, Guo Y, Gonzalez R, Berlin J . Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. J Surg Oncol. 2017; 117(2):284-289. DOI: 10.1002/jso.24834. View

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019; 394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6. View

Hauso O, Gustafsson B, Kidd M, Waldum H, Drozdov I, Chan A . Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008; 113(10):2655-64. DOI: 10.1002/cncr.23883. View

Warren W, Faber L, Gould V . Neuroendocrine neoplasms of the lung. A clinicopathologic update. J Thorac Cardiovasc Surg. 1989; 98(3):321-32. View

Walenkamp A, Sonke G, Sleijfer D . Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev. 2008; 35(3):228-36. DOI: 10.1016/j.ctrv.2008.10.007. View

Wang S, Zimmermann S, Parikh K, Mansfield A, Adjei A . Current Diagnosis and Management of Small-Cell Lung Cancer. Mayo Clin Proc. 2019; 94(8):1599-1622. DOI: 10.1016/j.mayocp.2019.01.034. View

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

10.

Yamaguchi T, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K . Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 2014; 105(9):1176-81. PMC: 4462387. DOI: 10.1111/cas.12473. View

11.

Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M . FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer. 2012; 19(6):751-7. DOI: 10.1530/ERC-12-0002. View

12.

Sorbye H, Welin S, Langer S, Vestermark L, Holt N, Osterlund P . Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2012; 24(1):152-60. DOI: 10.1093/annonc/mds276. View

13.

Robert C, Grob J, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E . Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019; 381(7):626-636. DOI: 10.1056/NEJMoa1904059. View

14.

Li J, Lu M, Lu Z, Li Z, Liu Y, Yang L . Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study. Oncotarget. 2016; 8(15):25669-25678. PMC: 5421960. DOI: 10.18632/oncotarget.12900. View

15.

Araki T, Takashima A, Hamaguchi T, Honma Y, Iwasa S, Okita N . Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract. Anticancer Drugs. 2016; 27(8):794-9. DOI: 10.1097/CAD.0000000000000393. View

16.

MOERTEL C, Kvols L, Oconnell M, Rubin J . Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991; 68(2):227-32. DOI: 10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i. View

17.

Olevian D, Nikiforova M, Chiosea S, Sun W, Bahary N, Kuan S . Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival. Hum Pathol. 2016; 49:124-34. DOI: 10.1016/j.humpath.2015.11.004. View

18.

Hainsworth J, Spigel D, Litchy S, Greco F . Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006; 24(22):3548-54. DOI: 10.1200/JCO.2005.05.0575. View

19.

Girardi D, Silva A, Rego J, Coudry R, Riechelmann R . Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. Cancer Treat Rev. 2017; 56:28-35. DOI: 10.1016/j.ctrv.2017.04.002. View

20.

Kim S, Ha S, Lee S, Ahn S, Lee J, Park S . The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. J Cancer. 2016; 7(5):484-9. PMC: 4780123. DOI: 10.7150/jca.13711. View